2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Kinesin
  5. Kinesin Isoform
  6. Kinesin Inhibitor

Kinesin Inhibitor

Kinesin Inhibitors (52):

Cat. No. Product Name Effect Purity
  • HY-132840
    Sovilnesib
    		Inhibitor 99.89%
    Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer.
  • HY-101770
    BTB-1
    		Inhibitor 99.75%
    BTB-1 is a potent, selective and reversible mitotic motor protein Kif18A inhibitor with an IC50 of 1.69 μM.
  • HY-153065
    KIF18A-IN-6
    		Inhibitor 98.56%
    KIF18A-IN-6 (Compound 134) is an orally active KIF18A inhibitor with an IC50 of 0.016 μM against KIF18A microtubule-dependent ATPase activity.
  • HY-144894
    AM-5308
    		Inhibitor 99.26%
    AM-5308 is a potent kinesin KIF18A inhibitor (WO2021211549A1, C13).
  • HY-164978
    KIF18A-IN-14
    		Inhibitor
    KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC50s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.
  • HY-170850
    MKLP2-IN-1
    		Inhibitor
    MKLP2-IN-1 (compound 12a) is an inhibitor of MKLP2 with good oral bioavailability. MKLP2-IN-1 inhibits the microtubule-stimulated ATPase activity of recombinant MKLP2 in vitro and suppresses tumor growth in a mouse Calu-6 lung cancer model.
  • HY-145034
    KIF18A-IN-1
    		Inhibitor 98.39%
    KIF18A-IN-1 is a mitotic kinesin KIF18A inhibitor extracted from patent WO2021026098A1 example 100-13. KIF18A-IN-1 exhibits anti-tumor activity.
  • HY-13224
    AZD4877
    		Inhibitor 99.49%
    AZD4877 is another isostere to Ispinesib (HY-50759)and also a kinesin spindle protein (Eg5) inhibitor with IC50 of 2 nM.AZD4877 arrests cell mitosis, leads to the formation of the monopolar spindle phenotype and induces apoptosis. AZD4877 inhibits circulating peripheral blood mononuclear cells (PBMCs) and has anti-cancer activity.
  • HY-115570
    GW406108X
    		Inhibitor ≥98.0%
    GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM in ATPase assays. GW406108X, a potent autophagy inhibitor, shows ATP competitive inhibition against ULK1 with a pIC50 of 6.37 (427 nM). GW406108X inhibits ULK1 kinase activity and blocks autophagic flux, without affecting the upstream signaling kinases mTORC1 and AMPK.
  • HY-153066
    VLS-1272
    		Inhibitor 98.09%
    VLS-1272 (Compound 22) is an orally active KIF18A inhibitor that binds to the KIF18A-microtubule complex in an ATP-noncompetitive manner (IC50 = 41 nM), blocking its ATPase activity and inhibiting microtubule translocation. This leads to abnormal accumulation of KIF18A at spindle poles, disrupting chromosome alignment and inducing mitotic arrest and apoptosis in CINHigh tumor cells (e.g., ovarian cancer OVCAR-3, breast cancer JIMT-1). VLS-1272 is a promising candidate for anti-tumor research.
  • HY-160441
    MC-Val-Cit-PAB-Ispinesib
    		Inhibitor 99.85%
    MC-Val-Cit-PAB-Ispinesib (Compound 509) is a potent inhibitor of Eg5. MC-Val-Cit-PAB-Ispinesib is a click chemistry reagent.
  • HY-145803
    KIF18A-IN-3
    		Inhibitor 99.30%
    KIF18A-IN-3 is a potent KIF18A inhibitor (IC50=61 nM). KIF18A-IN-3 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-3 can be used for researching cancer.
  • HY-162110
    AM-9022
    		Inhibitor 99.48%
    AM-9022 is an orally active, potent, selective KIF18A inhibitor that can be used for research on cancer.
  • HY-15187A
    (R)-Filanesib
    		Inhibitor 98.80%
    (R)-Filanesib ((R)-ARRY-520) is the R-enantiomer of Filanesib (HY-15187). Filanesib is a synthetic kinesin spindle protein (KSP) inhibitor with an IC50 of 6 nM.
  • HY-145802
    KIF18A-IN-2
    		Inhibitor 99.34%
    KIF18A-IN-2 is a potent KIF18A inhibitor (IC50=28 nM). KIF18A-IN-2 causes significant mitotic arrest and increases the number of mitotic cells in tumor tissues. KIF18A-IN-2 can be used for researching cancer.
  • HY-118961
    SR31527 chloride
    		Inhibitor
    SR31527 chloride is a potent KIFC1 inhibitor with an IC50 value of 6.6 µM. SR31527 chloride decreases cell viability and colony formation.
  • HY-15187B
    Filanesib TFA
    		Inhibitor
    Filanesib TFA (ARRY-520 TFA) is a selective kinesin spindle protein (KSP) inhibitor, with an IC50 of 6 nM for human KSP. Filanesib TFA induces cell death by apoptosis in vitro. Filanesib TFA has potent anti-proliferative activity.
  • HY-101071
    (S)-Monastrol
    		Inhibitor
    (S)-Monastrol ((+)-Monastrol) is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cancer cell lines. (S)-Monastrol arrests mammalian cells in mitosis with monopolar spindles.
  • HY-14661
    SB-743921 free base
    		Inhibitor
    SB-743921 free base is a potent selective inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM. SB-743921 free base can induce mitotic arrest, block cell cycle progression, induce apoptosis, and can be used in the research of myeloma, leukemia and other diseases.
  • HY-115570A
    (Z/E)-GW406108X
    		Inhibitor
    (Z/E)-GW406108X is a mixture of different configurations of GW406108X (HY-115570). GW406108X is a specific Kif15 (Kinesin-12) inhibitor with an IC50 of 0.82 uM.